Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.

ABSTRACT:

Background

In a landmark study, TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) examined the use of erythropoiesis-stimulating agent (ESA) therapy to treat anemia among patients with chronic kidney disease (CKD) and found no benefit compared to placebo.

Study design

A retrospective observational design was used to determine the impact of TREAT on clinical practice.

Setting & participants

A large US health plan database with more than 1.2 million claims for patients with non-dialysis-dependent CKD stages 3 and 4.

Factor

ESA prescribing 2 years before and after publication of TREAT.

Outcomes

Rate of ESA prescribing for ESA-naive and -prevalent cohorts.

Measurements

(1) Monthly ESA prescribing in the 2 years before and after public

SUBMITTER: Thamer M 

PROVIDER: S-EPMC4209337 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature